Last reviewed · How we verify
NCT07000513: ITEST-LAI
HIV Self-Testing and Long-Acting Injectables for HIV Treatment and Prevention Among Commercial Minibus Drivers (I-TEST LAIs) in Nigeria
Phase 4 trial testing ITEST-LAI in HIV in 400 participants. Not yet recruiting.
1 February 2029
Quick facts
| Lead sponsor | George Washington University |
|---|---|
| Phase | Phase 4 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 400 |
| Start date | 1 February 2026 |
| Primary completion | 1 February 2029 |
| Estimated completion | 1 August 2029 |
| Sites | 1 location across Nigeria |
Drugs / interventions tested
- ITEST-LAI
Conditions studied
- HIV — all drugs for HIV →
Sponsor
George Washington University
Who can join
18 and older, male only, with HIV. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Long-acting injectable antiretroviral therapy (LAI ART) and Pre-Exposure Prophylaxis (LAI PrEP) have the potential to transform HIV treatment and prevention, especially in reaching individuals such as commercial minibus drivers who have minimal or no contact with traditional health facilities. The project proposes to use a culturally appropriate and community-engaged approach to promote the uptake of HIV self-testing, LAI-ART, and LAI-PrEP among commercial minibus drivers in Nigeria by engaging commercial minibus drivers as peer educators/research facilitators.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07000513
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HIV
Currently open trials in the same condition.
- NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
- NCT07221214 — GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · recruiting
- NCT07226128 — The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV · NA · recruiting
- NCT07390474 — Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA i · Phase 1 · recruiting
- NCT07390955 — A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1 · Phase 1 · recruiting
Other George Washington University trials
Trials by the same sponsor.
- NCT07279129 — Decision Support Tool to Integrate PrEP Into Emergency Departments · Phase 1 · not yet recruiting
- NCT07524309 — Self-Help Plus Pilot Study, Colombia: Train2Care · NA · not yet recruiting
- NCT07249008 — NSS Grocery Store Brazil · NA · recruiting
- NCT07079306 — ChatGPT-Supported Text Messaging Program for Smoking Cessation · NA · not yet recruiting
- NCT06069869 — Multiple Micronutrient Supplementation (MMS) Iron Dose Acceptability Crossover Trial · Phase 3 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07000513 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by George Washington University
- Last refreshed: 1 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07000513.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing